Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

Published:2019-12-02 Issue:2 Volume:34 Page:159-170
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Dutta Binita,Huys Isabelle,Vulto Arnold G.^ORCID,Simoens Steven^ORCID

Funder

KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-019-00395-w.pdf

Reference46 articles.

1. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Semin Oncol. 2014;41(Suppl 3):S13–20. https://doi.org/10.1053/j.seminoncol.2014.03.009.

2. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. https://doi.org/10.1136/annrheumdis-2016-210715.

3. Heinemann L. Biosimilar insulin and costs: what can we expect? J Diabetes Sci Technol. 2015;10(2):457–62. https://doi.org/10.1177/1932296815605337.

4. European Medicines Agency GONAL-f. https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f. Accessed 14 Mar 2019.

5. Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics. 2017;35(10):1047–62. https://doi.org/10.1007/s40273-017-0529-x.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers;Exploration of Musculoskeletal Diseases;2024-09-10

2. Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience;Journal of Pediatric Health Care;2024-08

3. Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments;Pharmaceuticals;2024-07-10

4. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review;Survey of Ophthalmology;2024-07

5. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly;BioDrugs;2024-06-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3